Portrait

Dr. Christopher D. Southgate, PhD, JD

Patent Law Attorney
Attorney-at-Law

chris@cdslaw.org 857-366-2755 West Concord, MA

Services for you:

  • Due Diligence
  • IP Portfolio Strategy
  • Facilitating Matters with Outside Counsel
  • Freedom to Operate
  • Landscape Analysis
  • Patent Application and Prosecution
  • Patent Opposition Proceedings
  • PTAB Appeals
  • In-House Experience

  • PTC Therapeutics Inc.
  • Law Firm Experience

  • Private Practice — Remote
  • Gearhart Law — Elizabethtown, NJ
  • Lathrop & Gage — Boston, MA
  • Sughrue Mion — Washington, DC
  • Milstein, Zhang & Wu — Brookline, MA
  • Hiscock & Barclay — Boston, MA
  • Palmer & Dodge — Boston, MA
  • Scientific Research Experience

  • Brigham and Women's Hospital
  • Dana-Farber Cancer Institute
  • Harvard Biolabs
  • Tufts University School of Medicine
  • University of Massachusetts Medical Center
  • Harvard University
  • Qualifications

  • JD, American University, Washington College of Law — Washington, DC, 2013
  • Patent Agent, US Patent and Trademark Office, 2003
  • PhD, Molecular Biology, University of Zurich — Switzerland, 1989
  • Diploma, Swiss Institute for Experimental Cancer (ISREC), University of Lausanne — Switzerland, 1982
  • BS, Biology, University of Lausanne — Switzerland, 1981
  • Inventorship

  • US Patent No. 8,574,567 — “Multipotent stem cells and uses thereof”
  • European Patent No. 2155860 — “Multipotent stem cells and uses thereof”
  • International Background

  • English (native)
  • French (fluent)
  • German (intermediate understanding)
  • Exemplary Subjects

  • adult and embryonic stem cell therapies
  • angiogenesis inhibitors
  • antibody glycoforms
  • antibody hinge and Fc variants
  • anti-tumor therapies
  • aptamers
  • biodegradable plastics
  • biofuels
  • cancer stemness inhibitors
  • cancer stem cell biomarkers
  • checkpoint inhibitors
  • combinatorial therapies
  • dietary supplements
  • discovery platform technologies
  • epigenetics (including HDACs)
  • genomics
  • heart valves
  • IgG glycobiology
  • inducible gene expression systems
  • mammalian expression vectors
  • medical diagnostics
  • medical devices
  • microRNAs
  • orthopedics
  • PCR applications
  • recombinant antibody platform technologies
  • recombinant TCR/neoantigen selection
  • RNAi nanoparticle formulations
  • RNAi platform technologies
  • stem cell assays
  • target-specific and multi-specific antibodies
  • TCR co-receptors
  • tissue bioengineering and patterning
  • x-ray crystallography
  • Exemplary Drafted Patents

  • US9376499B2:PAR-1 ACTIVATION BY METALLOPROTEINASE-1 (MMP-1)
  • US7910325B2:METHOD FOR DETERMINATION AND QUANTIFICATION OF RADIATION OR GENOTOXIN EXPOSURE
  • US9039764B2:ELECTROCHEMICAL COUPLING OF METALLIC BIOMATERIAL IMPLANTS FOR BIOLOGICAL EFFECT
  • US8524451B2:METHOD FOR REAL-TIME DETECTION OF SALMONELLA IN FOOD USING A CLEAVABLE CHIMERIC PROBE
  • US8092361B2:SPLIT SPIN CENTRIFUGATION OF TEST ELEMENTS
  • US8323585:USE OF FLUID ASPIRATION-DISPENSING TIP AS A MICROCENTIFUGE TUBE
  • US8551122B2:HANDHELD SAFETY SUTURING DEVICE
  • US7850917:PARTICLE AGGLUTINATION IN A TIP
  • US20160138103A1:DIAGNOSTIC BIOMARKERS OF DIABETES
  • US20120219945A1:USE OF SINGLE-STRANDED BINDING PROTEIN IN AMPLIFYING TARGET NUCLEIC ACID
  • US20130209987A1:OLIGONUCLEOTIDE SETS FOR DETECTION OF HUMAN PAPILLOMAVIRUS
  • US20160046936A1:BIODEGRADABLE AND CLINICALLY-COMPATIBLE NANOPARTICLES AS DRUG DELIVERY CARRIERS
  • WO2016196935A1:COMPOSITIONS COMPRISING A CANCER STEMNESS INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT FOR USE IN TREATING CANCER
  • WO2017100127 Al:ASYMMETRIC INTERFERING RNAs, AND COMPOSITIONS, USE, OR PREPARATION THEREOF
  • WO2011/126482A1:IMMUNOASSAY FOR THE DIAGNOSIS OF PROSTATE CANCER
  • WO2009/151688:DIRECT SELECTION OF STRUCTURALLY DEFINED APTAMERS
  • WO2018160887A1:PDL1-SPECIFIC AND BETA-CATENIN-SPECIFIC ASYMMETRIC INTERFERING RNA COMPOSITIONS, USES OR PREPARATION THEREOF
  • WO2017023866A1:METHOD OF TARGETING STAT3 AND OTHER NON-DRUGGABLE PROTEINS
  • WO2018098352A2:TARGETING KRAS INDUCED IMMUNE CHECKPOINT EXPRESSION
  • chris@cdslaw.org          857-366-2755